Special situations in epilepsy: Women and the elderly

Neurologist

Volumn 13, Issue 6 SUPPL. 1, 2007, Pages

  Forcadas, María Isabel ^a   Peña Mayor, Pilar ^b   Puig, Javier Salas ^c  

^a HOSPITAL DE CRUCES   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Adverse effects; Lactation; Polypharmacy; Special issues in women with epilepsy; Teratogenicity

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ACETAZOLAMIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLOMIFENE; CONTRACEPTIVE AGENT; DIAZEPAM; ESTROGEN; ETIRACETAM; FELBAMATE; GABAPENTIN; GONADORELIN; LAMOTRIGINE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; PROGESTERONE; SEX HORMONE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ATAXIA; BONE METABOLISM; CATAMENIAL EPILEPSY; CLINICAL TRIAL; COGNITIVE DEFECT; CONTRACEPTION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DIZZINESS; DROWSINESS; DRUG DOSE TITRATION; ENDOCRINE FUNCTION; EPILEPSY; FERTILITY; FETUS DEVELOPMENT; GAIT DISORDER; GERIATRICS; HUMAN; INCIDENCE; LACTATION; LANGUAGE DISABILITY; MEMORY DISORDER; MENOPAUSE; MONITORING; MORBIDITY; NONHUMAN; OSTEOPOROSIS; PERIPHERAL EDEMA; POPULATION RESEARCH; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; PUERPERIUM; RECURRENCE RISK; REPRODUCTION; REVIEW; SEIZURE; SEX DIFFERENCE; SEXUAL FUNCTION; SIDE EFFECT; SLEEP APNEA SYNDROME; SOMNOLENCE; THROMBOCYTOPENIA; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

EPILEPSY; FEMALE; GERIATRICS; GONADAL STEROID HORMONES; HUMANS; MALE; MENOPAUSE; PREGNANCY; WOMEN'S HEALTH;

EID: 37349044579     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e31815c613d     Document Type: Review

References (65)

1. Practice parameter: management issues for women with epilepsy (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1998;51:944-948.
2. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1989;30:389-399.
3. Reddy DS. Role of neurosteroids in catamenial epilepsy. Epilepsy Res. 2004;62:99-118.
4. Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia. 2005;46(Suppl 9):117-124.
5. Bauer J, Isojarvi JI, Herzog AG, et al. Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management. J Neurol Neurosurg Psychiatr. 2002;73:121-125.
6. Isojarvi JI. Reproductive dysfunction in women with epilepsy. Neurology. 2003;61(6 Suppl 2):S27-34.
7. Morrell M, Hyes F, Slus P, et al. Higher incidence of components of polycystic ovary syndrome in young women with epilepsy treated with valproate Vs lamotrigine. Epilepsia. 2005;46(Suppl 6):71.
8. Morrell MJ, Montouris GD. Reproductive disturbances in patients with epilepsy. Cleve Clin J Med. 2004;71(Suppl 2):S19-S24.
9. Harden CL, Labar DR, Koppel BS, et al. Factors influencing the age at menopause of women with epilepsy. Epilepsia. 2002;43(Suppl 7):231-232.
10. Harden CL, Pulver MC, Ravdin L, et al. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia. 1999;40:1402-1407.
11. Harden CL, Herzog AG, Nikolov BG, et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia. 2006;47:1447-1451.
12. Pack AM, Gidal B, Vazquez B. Bone disease associated with antiepileptic drugs. Cleve Clin J Med. 2004;71(Suppl 2):S42-S48.
13. Harden CL. Menopause and bone density issues for women with epilepsy. Neurology. 2003;61(6 Suppl 2):S16-S22.
14. Vestergaard P. Epilepsy, osteoporosis and fracture risk - a meta-analysis. Acta Neurol Scand. 2005;112:277-286.
15. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332:767-773.
16. Ali II, Schuh L, Barkley GL, et al. Antiepileptic drugs and reduced bone mineral density. Epilepsy Behav. 2004;5:296-300.
17. Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia. 1996;37(Suppl 6):S34-S44.
18. Peña P, Forcadas M, Martinez M. Anticoncepción y Epilepsia. Epilepsia y Mujer. 2002:39-50.
19. Doose DR, Wang SS, Padmanabhan M, et al. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia. 2003;44:540-549.
20. Tatum WOt, Liporace J, Benbadis SR, et al. Updates on the treatment of epilepsy in women. Arch Intern Med. 2004;164:137-145.
21. Mayor S. NICE gives guidance on use of new antiepileptic drugs in children. BMJ. 2004;328:1093.
22. Perucca E. NICE guidance on newer drugs for epilepsy in adults. BMJ. 2004;328:1273-1274.
23. Sabers A, Ohman I, Christensen J, et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology. 2003;61:570-571.
24. Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia. 2007;48:484-489.
25. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006;77:193-198.
26. Tomson T, Battino D, Bonizzoni E, et al. EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia. 2004;45:1463-1464.
27. Holmes LB, Wyszynski DF. North American antiepileptic drug pregnancy registry. Epilepsia. 2004;45:1465.
28. Vajda FJ, O'Brien TJ, Hitchcock A, et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci. 2004;11:854-858.
29. Isojarvi J, Cunnington M, Messenheimer JA. Twelve years of monitoring through an international observational study of pregnancy outcome following exposure to lamotrigine. Epilepsia. 2005;46(Suppl 6):110.
30. Adab N, Tudur SC, Vinten J, et al. Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database Syst Rev. 2004(3):CD004848.
31. Yerby MS. Clinical care of pregnant women with epilepsy: neural tube defects and folic acid supplementation. Epilepsia. 2003;44(Suppl 3):33-40.
32. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology. 2006;66:354-360.
33. Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology. 2003;61(6 Suppl 2):S35-S42.
34. Penovich PE, Eck KE, Economou VV. Recommendations for the care of women with epilepsy. Cleve Clin J Med. 2004;71(Suppl 2):S49-S57.
35. Tettenborn B, Genton P, Polson D. Epilepsy and women's issues: an update. Epileptic Disord. 2002;4(Suppl 2):S23-S31.
36. Forcadas M, Martinez M. Epilepsia y Lactancia. Epilepsia y Mujer. 2002:135-147.
37. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343:118-126.
38. Johannessen SI, Helde G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia. 2005;46:775-777.
39. Hauser WA. Epidemiology of Seizures and Epilepsy in the Elderly. New York: Butterworth-Heinemann, 1997.
40. Hiyoshi T, Yagi K. Epilepsy in the elderly. Epilepsia. 2000;41(Suppl 9):31-35.
41. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005;64:1868-1873.
42. Cleary P, Shorvon S, Tallis R. Late-onset seizures as a predictor of subsequent stroke. Lancet. 2004;363:1184-1186.
43. Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. Neurology. 2004;62(5 Suppl 2):S24-S29.
44. Collins NS, Shapiro RA, Ramsay RE. Elders with epilepsy. Med Clin North Am. 2006;90:945-966.
45. Van Cott AC. Epilepsy and EEG in the elderly. Epilepsia. 2002;43(Suppl 3):94-102.
46. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 1985;313:145-151.
47. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med. 1992;327:765-771.
48. Morrell MJ, McLean MJ, Willmore LJ, et al. Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. The Steps Study Group. Seizure. 2000;9:241-248.
49. Ferrendelli JA, French J, Leppik I, et al. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. Epilepsy Behav. 2003;4:702-709.
50. Morrell MJ, Leppik I, French J, et al. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res. 2003;54:153-161.
51. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs. II: Treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62:1261-1273.
52. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs. I: Treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62:1252-1260.
53. Birnbaum A, Hardie N, Leppik I. Variability of total phenytoin serum concentrations within elderly nursing home residents. Neurology. 2003;60:555-559.
54. Lackner TE. Strategies for optimizing antiepileptic drug therapy in elderly people. Pharmacotherapy. 2002;22:329-364.
55. Saetre E, Perucca E, Isojarvi J, et al. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia. 2007;48:1292-1302.
56. Blum D, Meador K, Biton V, et al. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology. 2006;67:400-406.
57. Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet. 2006;45:351-363.
58. Bauer J, Ben-Menachem E, Kramer G, et al. Levetiracetam: a long-term follow-up study of efficacy and safety. Acta Neurol Scand. 2006;114:169-176.
59. Leppik IE, Birnbaum A. Epilepsy in the elderly. Semin Neurol. 2002;22:309-320.
60. Bergey GK. Initial treatment of epilepsy: special issues in treating the elderly. Neurology. 2004;63(10 Suppl 4):S40-S48.
61. Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004;45:20-27.
62. Ryvlin P. Defining success in clinical trials-profiling pregabalin, the newest AED. Eur J Neurol. 2005;12(Suppl 4):12-21.
63. Beydoun A, Uthman B, Ramsay R, et al. Pregabalin add-on trial: a double-blind, multicenter study in patients with partial epilepsy. Epilepsia. 1999;40:108.
64. Zaccara G, Messori A, Cincotta M, et al. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand. 2006;114:157-168.
65. Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure. 2007;16:296-304.